If you’re looking to stay up to date with the latest commercialization news out of the Office of Research and Technology Management at ÐÇ¿Õ´«Ã½, you’ve come to the right place. Explore some of our latest headlines relating to inventions, startups and more from researchers at ÐÇ¿Õ´«Ã½.
2025
PR Newswire | March 11, 2025
Trailhead Biosystems | March 5, 2025
BusinessWire | Feb. 11, 2025
NervGen | Feb. 6, 2025
PR Newswire | Feb. 5, 2025
EU-Startups.com | Jan. 28, 2025
Crain’s Cleveland Business | Jan. 17, 2025
Energy.gov | Jan. 8, 2025
2024
University Hospitals | Dec. 17, 2024
Forbes | Dec. 11, 2024
Global NewsWire | Nov. 14, 2024
PR Newswire | Oct. 29, 2024
FreshWater | Oct. 24, 2024
NutraIngredients USA | Oct. 16, 2024
PR Newswire | Sept. 26, 2024
MetroHealth | Sept. 9, 2024
PR Newswire | Aug. 28, 2024
News 5 Cleveland | Aug. 22, 2024
University Hospitals | Aug. 9, 2024
The Daily | July 12, 2024
NervGen | June 25, 2024
WKYC | April 21, 2024
DefiniGEN | June 3, 2024
Crain’s Cleveland Business | March 18, 2024
PR Newswire | March 7, 2024
Crain’s Cleveland Business | Feb. 20, 2024
The Daily | Feb. 19, 2024
BusinessWire | Feb. 1, 2024
The Daily | Jan. 5, 2024
2023
Amgen.com | Nov. 28, 2023
Luciddx.com | Oct. 31, 2023
Nervgen.com | Oct. 23, 2023
Nervgen.com | Sept. 25, 2023
Bioinformant | Sept. 18, 2023
Cleveland.com | July 25, 2023
Crain's Cleveland Business | July 11, 2023
PAVmed | May 11, 2023
AUTM | April 21, 2023
PAVmed | April 18, 2023
NervGen | April 13, 2023
NervGen | March 30, 2023
NutraIngredients USA | March 16, 2023
Cleveland.com | March 15, 2023
The Daily | March 8, 2023
The Business Journal Daily | March 8, 2023
The Daily | Feb. 23, 2023
Crain's Cleveland Business | Feb. 23, 2023
PAVmed | Feb. 15, 2023
The Daily | Feb. 14, 2023
NervGen | Feb. 14, 2023
The Daily | Feb. 13, 2023
Fox 8 WJW | Feb. 7, 2023
Forbes | Jan. 27, 2023
The Plain Dealer | Jan. 26, 2023
Ideastream Public Media | Jan. 26, 2023
Drug Discovery and Development | Jan. 18, 2023
The Daily | Jan. 17, 2023
2022
Lucid Diagnostics | Dec. 8, 2022
The Daily | Dec. 8, 2022
Lucid Diagnostics | Dec. 1, 2022
Exclusive license agreement with ÐÇ¿Õ´«Ã½ for Core-NK platform
Chimeric Therapeutics | Nov. 21, 2022
PAVmed | Dec. 1, 2022
PAVmed | Dec. 8, 2022
The Daily | Dec. 8, 2022
The Daily | Nov. 21, 2022
Ohio Department of Development | Oct. 18, 2022
NervGen | Oct. 25, 2022
The Daily | Sept. 14, 2022
The Daily | Sept. 8, 2022
The Daily | Sept. 8, 2022
The Daily | Sept. 9, 2022
Folio Photonics Announces Breakthrough Multi-Layer Optical Disc Storage Technology to Enable Industry-Disruptive Cost, Cybersecurity and Sustainability Benefits
Folio Photonics | Aug. 30, 2022
PAVmed | Aug. 11, 2022
NervGen | Aug. 10, 2022
Lucid Diagnostics | Aug. 4, 2022
BusinessWire | Aug. 3, 2022
NervGen | Aug. 2, 2022
PAVmed | Aug. 2, 2022
NervGen | July 14, 2022
RAD adds brain tumor technology to portfolio
Radiopharm Theranostics | June 9, 2022
The Daily | May 25, 2022
AccessWire | May 12, 2022
PAVmed | May 9, 2022
PAVmed | April 4, 2022
NervGen Presenting Interim Phase 1 Clinical Trial Data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting
NervGen | March 31, 2022
PAVmed | March 24, 2022
PAVmed | March 23, 2022
NervGen | March 15, 2022
PAVmed | March 3, 2022
The Daily | Feb. 11, 2022
The Daily | Jan. 27, 2022
News 5 Cleveland | Jan. 21, 2022
The Daily | Jan. 20, 2022
Crain's Cleveland Business | Jan. 20, 2022
Crain's Cleveland Business | Jan. 19, 2021
The Daily | Jan. 5, 2022
2021
NervGen | Dec. 22, 2021
The Daily | Dec. 22, 2021
PAVmed | Dec. 1, 2021
Global NewsWire | Nov. 30, 2021
NervGen Pharma Corp. Closes Non-Brokered Private Placement
NervGen | Nov. 29, 2021
First Point-of-Care Test for Serious Hemoglobin Disorder, Beta Thalassemia, Provides New Weapon for the Front Lines of Healthcare Worldwide
Hemex Health | Nov. 24, 2021
NervGen | Nov. 18, 2021
Lucid Diagnostics | Nov. 11, 2021
NervGen | Nov. 4, 2021
Lucid Diagnostics | Oct. 28, 2021
The Daily | Oct. 20, 2021
NervGen | Oct. 18, 2021
PAVmed | Oct. 13, 2021
Crain's Cleveland Business | Oct. 8, 2021
NervGen Pharma | Sept. 27, 2021
Crain's Cleveland Business | Sept. 24, 2021
PAVmed | Sept. 23, 2021
Fierce Biotech | Sept. 23, 2021
PAVmed: A Small Cap Puts Its Streamlined Development Model to the Test
MyStrategist.com/MedTech-Strategist | Aug. 19, 2021
Business Wire | Aug. 10, 2021
Business Insider | Aug. 9, 2021
MedTech Strategist | Aug. 2, 2021
PRNewswire | July 22, 2021
AUTM | July 16, 2021
Neuros Medical | June 29, 2021
BusinessWire | June 28, 2020
Stockhouse | June 28, 2021
TechOhio, June 24, 2021
The Daily | June 15, 2021
PAVmed | June 10, 2021
NervGen | June 10, 2021
MedLumics | May 28, 2021
PAVmed | May 26, 2021
NervGen | May 20, 2021
The Daily | May 7, 2021
NervGen | May 6, 2021
The Daily | May 5, 2021
The Daily | April 29, 2021
Diagnostic Imagining | April 25, 2021
NervGen Pharma | April 22, 2021
Eurek Alert | April 22, 2021
Crain's Cleveland Business | April 20, 2021
FreshWater Cleveland | April 22, 2021
Business Wire | April 13, 2021
The Daily | April 8, 2021
The Daily | March 31, 2021
PRNewswire | March 30, 2021
The PharmaLetter | March 30, 2021
Equalize | Feb. 18, 2021
NervGen | March 8, 2021
NervGen | March 2, 2021
PAVmed | Feb. 22, 2021
The Daily | Feb. 11, 2021
NervGen | Jan. 27, 2021
NervGen’s 2020 in Review and the Plan Ahead
NervGen | Jan. 11, 2021
Neuros Medical | Jan. 6, 2021
Neuros Medical | Jan. 6, 2021
Dravet Syndrome News | Jan. 5, 2021
NervGen Pharma | Jan. 5, 2021